MicrosensDx Information

With a strong record of commercialising inventions, MicrosensDx’s IP portfolio expands from sepsis to sample preparation and protein aggregation. The company applies its substantive experience in developing diagnostics to make improvements in healthcare both possible and universally deployable. Based on the company’s IP, MicrosensDx's pioneer product, the ox-PTX3 test, is a novel blood test for sepsis, which measures specific forms of pentraxin (PTX3) and can be used to diagnose sepsis, risk profile patients and monitor treatment. Its ‘dual-sensor’ approach provides unique insights that current tests cannot. MicrosensDx is based in Cambridge, close to one of the UK’s most dynamic life science clusters.